ライフサイエンスコーパス: fresh frozen plasma

1 and avoidance of preemptive transfusions of fresh frozen plasma.

2 2,058 nontrauma patients who did not receive fresh frozen plasma.

3 o did receive red blood cells in addition to fresh frozen plasma.

4 ion for patients receiving and not receiving fresh frozen plasma.

5 and nonleukoreduced red cells, platelets, or fresh-frozen plasma.

6 platelets (0.86 U vs. 0.24 U, p = 0.001) and fresh frozen plasma (0.68 U vs. 0.24 U, p = 0.015).

7 ts (0.1 [0.04] vs 1.9 U [4.5] p=0.0001), and fresh-frozen plasma (0.1 [0.07] vs 0.75 U [0.21] p=0.000

8 ut also the proportion of patients requiring fresh frozen plasma (21.1% vs. 48.3%, P = 0.025).

9 s of platelets (10.0 versus 6.6 U, P<0.012), fresh frozen plasma (4.8 versus 3.1 U, P<0.03), and cryo

10 platelets, 12.5 +/- 5.4 U vs. 8.6 +/- 6.4 U; fresh frozen plasma, 9.6 +/- 4.9 U vs. 4.9 +/- 3.6 U; an

11 The dose of fresh-frozen plasma administered was highly variable (me

12 ood products (red blood cells, platelets, or fresh frozen plasma) administered during transplantation

13 ulopathy unresponsive to vitamin K requiring fresh-frozen plasma after the first 24 hours postresecti

14 ents who received a total of 46,101 units of fresh frozen plasma and 6,251 units of apheresis platele

15 The relative risk for transfusion of fresh frozen plasma and all infections was 2.99 (2.28-3.

16 ransfusion of high plasma volume components, fresh frozen plasma and apheresis platelets, from potent

17 analysis to evaluate the association between fresh frozen plasma and infectious complication, control

18 gnificant dose-response relationship between fresh frozen plasma and infectious complications (p = .0

19 The association between fresh frozen plasma and infectious complications remaine

20 ine concentrations, the amount of platelets, fresh frozen plasma and packed erythrocytes used, and th

21 nd anemia were corrected with transfusion of fresh frozen plasma and packed red blood cells.

22 or the continued unbridled administration of fresh frozen plasma and platelets without objective evid

23 ave shown to reduce bleeding, transfusion of fresh frozen plasma and platelets, and possibly mortalit

24 ns to platelets is the highest compared with fresh frozen plasma and red blood cells.

25 association was found between transfusion of fresh frozen plasma and ventilator-associated pneumonia

26 both platelets and coagulant products (e.g., fresh-frozen plasma and recombinant-activated factor VII

27 core analysis adjusting by use of platelets, fresh frozen plasma, and cryoprecipitate; and adjusting

28 h a 68%, 56%, and 58% reduction in platelet, fresh frozen plasma, and packed erythrocyte usage, respe

29 used patients, pooled platelet concentrates, fresh frozen plasma, and packed red cells collected usin

30 ng administration of packed red blood cells, fresh frozen plasma, and platelets in ratios approximati

31 from 7.8% to 92.8% for RBCs, 0% to 97.5% for fresh-frozen plasma, and 0.4% to 90.4% for platelets.

32 C1 inhibitor concentrates and fresh frozen plasma are available for acute intervention

33 Tranexamic acid or virally inactivated fresh frozen plasma can be used for long-term prophylaxi

34 Transfused red cells, platelets, and fresh-frozen plasma can transmit West Nile virus.

35 The value of fresh frozen plasma components, both standard and steril

36 use of a combination of packed red cells and fresh-frozen plasma during surgery for congenital heart

37 anticoagulation, and/or plasmapheresis with fresh-frozen plasma exchange, resolved TMA in most patie

38 ns for use of other blood components such as fresh frozen plasma (FFP) and platelet transfusions are

39 sought to define the overall utilization of fresh frozen plasma (FFP) and platelets and the impact o

40 tments utilized in clinical practice include fresh frozen plasma (FFP) and prothrombin complex concen

41 ) and is used to justify preprocedure use of fresh frozen plasma (FFP) and/or platelets (PLT).

42 re in the critically ill, data on the use of fresh frozen plasma (FFP) are limited.

43 duct, human polyclonal antibody, obtained as fresh frozen plasma (FFP) from a HPS survivor.

44 from Iraq supporting early aggressive use of fresh frozen plasma (FFP) in a 1:1 ratio to packed red b

45 plasma volume was removed and replaced with fresh frozen plasma (FFP) or with 50% FFP and 50% albumi

46 Because the administration of fresh frozen plasma (FFP) prevents gastrointestinal blee

47 The practice of a high transfusion ratio of fresh frozen plasma (FFP) to red blood cells (RBCs) has

48 We assessed the safety and efficacy of fresh frozen plasma (FFP) versus prothrombin complex con

49 amounts of packed red blood cells (RBCs) and fresh frozen plasma (FFP) were recorded during hospital

50 ross as a virally inactivated alternative to fresh-frozen plasma (FFP).

51 8 U blood products (red blood cells [RBCs] + fresh frozen plasma [FFP] + platelets) had a median (int

52 otal of 380 non-trauma patients who received fresh frozen plasma from 2004 to 2005 were compared with

53 ciation between infection and transfusion of fresh frozen plasma in patients who did not receive conc

54 e vWf-cleaving metalloprotease is present in fresh-frozen plasma, in cryoprecipitate-depleted plasma

55 The severe group required more fresh-frozen plasma intraoperatively than the mild group

56 Transfusion of fresh frozen plasma is associated with an increased risk

57 cation of these patients is critical so that fresh frozen plasma may be avoided.

58 o >1.5) or clinical (transfusion >2 units of fresh frozen plasma or >1 pack of platelets in 6 hours)

59 six allografts lost, despite treatment with fresh-frozen plasma or plasmapheresis.

60 red blood cells, platelet concentrates, and fresh frozen plasma over the routine storage time.

61 ion of packed red blood cells (p = .442) and fresh frozen plasma (p = .063) were not different betwee

62 ess was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP).

63 ive bleeding disorder treated by infusion of fresh-frozen plasma, plasma-derived FVII concentrates an

64 re frequent recurrences, and prescription of fresh-frozen plasma prophylaxis.

65 The administration of coagulation factors (fresh frozen plasma, prothrombin complex concentrates or

66 The mean packed red blood cells to fresh frozen plasma ratio changed from 2.6:1 during the

67 Higher fresh frozen plasma ratios (> 1:2) were not associated w

68 use of a combination of packed red cells and fresh-frozen plasma (reconstituted blood) for priming of

69 r bias improved survival outcome with higher fresh frozen plasma: red blood cell ratios.

70 ction without prior PVE demonstrated a lower fresh frozen plasma requirement (P = 0.01), a lower peak

71 VE than the PVE group, as were postoperative fresh-frozen plasma requirements.

72 95% confidence interval [CI], 0.57 to 0.99), fresh frozen plasma (RR, 0.37; 95% CI, 0.21 to 0.64), an

73 Fresh-frozen plasma should be given for documented defic

74 ontinued, and treatment with plasmapheresis, fresh frozen plasma, steroids, and OKT3 was begun.

75 ence of reactions to platelets compared with fresh frozen plasma suggests that a platelet-related fac

76 Fresh frozen plasma-to-packed RBCs and platelets-to-pack

77 The benefits of higher ratios of fresh frozen plasma-to-packed RBCs and platelets-to-pack

78 with an odds ratio of infection per unit of fresh frozen plasma transfused equal to 1.039 (1.013-1.0

79 -test allowed comparison of average units of fresh frozen plasma transfused to patients with and with

80 rative packed red cells (r=0.28, P=.049) and fresh frozen plasma transfusions (r=0.42, P=.004), highe

81 nternational normalized ratios, 33% received fresh-frozen plasma transfusions during their intensive

82 Wide variation in fresh-frozen plasma treatment exists suggesting clinical

83 Fifty-one percent of fresh-frozen plasma treatments were to nonbleeding patie

84 of platelet units (4.3 vs. 1.7, p =.05) and fresh frozen plasma units (1.1 vs. 0.6, p =.08) also was

85 tests) and the transfusion (blood units and fresh frozen plasma units) during the operative period w

86 id infusion volume (6.1-3.2 L) and increased fresh frozen plasma use (3.2-10.1 U) (both P < .05) in t

87 apy and treatment with lactulose, vitamin K, fresh frozen plasma, ventilatory assistance, and intensi

88 unoglobulin (4 cases), interferon (3 cases), fresh frozen plasma with WNV IgG (2 cases), and ribaviri